Source: CentralCharts

Press Release: Sierra Oncology : Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration

- Sierra to discuss clinical findings and possible next steps for SRA737 at Analyst & Investor Event at 6:00 am CT on June 3, 2019 featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit -

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Stephen Dilly's photo - President & CEO of Sierra

President & CEO

Stephen Dilly

CEO Approval Rating

90/100

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more